

## S 1095

Stop STALLING Act

**Congress:** 119 (2025–2027, Current)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Mar 24, 2025

**Current Status:** Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.

**Latest Action:** Placed on Senate Legislative Calendar under General Orders. Calendar No. 45. (Apr 10, 2025)

**Official Text:** <https://www.congress.gov/bill/119th-congress/senate-bill/1095>

### Sponsor

**Name:** Sen. Klobuchar, Amy [D-MN]

**Party:** Democratic • **State:** MN • **Chamber:** Senate

### Cosponsors (6 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Blumenthal, Richard [D-CT]	D · CT		Mar 24, 2025
Sen. Booker, Cory A. [D-NJ]	D · NJ		Mar 24, 2025
Sen. Cruz, Ted [R-TX]	R · TX		Mar 24, 2025
Sen. Durbin, Richard J. [D-IL]	D · IL		Mar 24, 2025
Sen. Grassley, Chuck [R-IA]	R · IA		Mar 24, 2025
Sen. Welch, Peter [D-VT]	D · VT		Mar 24, 2025

### Committee Activity

Committee	Chamber	Activity	Date
Judiciary Committee	Senate	Reported By	Apr 10, 2025

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

*No related bills are listed.*

**Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act**

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit is subject to civil penalties, such as a fine of up to \$50,000 for each day that the FDA spent reviewing the baseless petition.





